RxDoctor Payments Data

Rodolfo Longoria, MD

Internal Medicine · Brownsville, TXNPI 1720398951

Payments from drug & device makers

$1,563in general payments, 2019–2025

Across 57 payments — averaging $27.43 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$415
  • AstraZeneca$346
  • Lilly USA, LLC$338
  • AbbVie$123
  • GSK$123
  • Amgen$52
  • plus $166 from 7 others

What the payments were for

  • Food & beverage$1,563100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,563 in reported general payments places this provider in the 75th percentile of 7,675 internal medicine providers in Texas.

See all internal medicine providers in Texas

Medicare billing

Part B allowed, 2024
$11,812
Medicare patients
45
Services billed
163

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RybelsusSemaglutide99$166,100
OzempicSemaglutide69$95,256
FarxigaDapagliflozin Propanediol57$68,804
JardianceEmpagliflozin37$55,656
JanuviaSitagliptin Phosphate29$35,609
MounjaroTirzepatide16$24,743
SynjardyEmpagliflozin/Metformin Hcl12$12,933
EliquisApixaban11$11,611
Tresiba Flextouch U-200Insulin Degludec12$11,042
Lantus SolostarInsulin Glargine,hum.Rec.Anlog12$2,265
Atorvastatin Calcium213$1,906
Tamsulosin Hcl138$1,816
Rosuvastatin Calcium93$1,751
Losartan Potassium111$1,162
Dutasteride32$1,138

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskRybelsus, Ozempic$415$261,356168 claims
AstraZenecaFarxiga$346$68,80457 claims
Boehringer IngelheimJardiance, Synjardy$25$68,59049 claims
Lilly USA, LLCMounjaro$338$24,74316 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 7,675 internal medicine providers in Texas.

Other internal medicine in Brownsville

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →